OR8G5 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin may elevate intracellular cAMP, initiating a cascade that culminates in the downregulation of OR8G5 by altering the binding affinity of cAMP-responsive element binding (CREB) proteins at the gene's promoter. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 could diminish OR8G5 transcription by competitively inhibiting the interaction between bromodomain-containing 4 (BRD4) proteins and acetylated histones near the OR8G5 gene, thereby reducing the recruitment of transcriptional machinery. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A has the potential to decrease OR8G5 expression by inhibiting histone deacetylases, which would maintain histones in an acetylated state, leading to a closed chromatin conformation that is less accessible for transcription at the OR8G5 locus. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine could lead to the hypomethylation of CpG islands within the OR8G5 gene promoter, potentially decreasing the binding of methyl-CpG-binding domain proteins and repressive histone marks, which results in reduced transcription initiation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 may attenuate OR8G5 expression by inhibiting the activity of MEK1/2, which are upstream of ERK1/2 in the MAPK pathway, thereby decreasing the phosphorylation and activation of transcription factors that normally increase OR8G5 gene expression. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $80.00 $175.00 | 28 | |
GW501516 could suppress OR8G5 expression by activating peroxisome proliferator-activated receptor delta (PPARδ), which may repress transcription factors or coactivators essential for OR8G5 gene transcription. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may reduce OR8G5 protein levels by inhibiting the mTOR pathway, leading to a decline in cap-dependent translation, which is crucial for the synthesis of many GPCR proteins, including OR8G5. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 could curtail OR8G5 expression by inhibiting phosphatidylinositol 3-kinase (PI3K), resulting in decreased activation of AKT signaling and subsequent transcription factor activity necessary for OR8G5 gene expression. | ||||||
Wnt-C59 | 1243243-89-1 | sc-475634 sc-475634A sc-475634B | 5 mg 10 mg 50 mg | $210.00 $320.00 $1250.00 | 1 | |
Wnt-C59 may inhibit the expression of OR8G5 by antagonizing Wnt/β-catenin signaling, which can result in decreased transcription of Wnt target genes, including potentially those of the GPCR family such as OR8G5. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $99.00 $335.00 $836.00 $2099.00 | 47 | |
DAPT has the potential to decrease OR8G5 expression by inhibiting gamma-secretase activity, which is necessary for Notch receptor processing and the subsequent release of the Notch intracellular domain that can drive gene expression. | ||||||